MetaVia is trading at $1.50, up +11.92% versus the October 8 regular-session close; no verified company-specific catalyst or direct explanation for the after-hours rise was identified. - MetaVia’s investor-relations page lists a September 9 release about preclinical findings for DA-1726 as its latest company announcement, not news dated October 8. - Broader market context was mixed and does not clearly explain the move; the reason remains uncertain.